Sab Biotherapeutics, Inc. · NASDAQ:SABS
Sab Biotherapeutics — SPAC Merger (June 2021)
32 slides from Sab Biotherapeutics's SPAC merger presentation, Jun 22, 2021
Slide 1: Advancing Powerful New Class of Immunotherapeutic Antibodies
2 ¥/ BIOTHERAPEUTICS ADVANCING POWERFUL NEW CLASS OF IMMUNOTHERAPEUTIC ANTIBODIES JUNE 2021 © 2021 SAB BIOTHERAPEUTICS, INC. - CONFIDENTIAL
Slide 2: Legal Disclaimer
Legal Disclaimer About this Presentation This presentation is for informational purposes only to assist interested parties in making their own evaluation with respect to the Proposed Business Combination (the “Proposed Business Combination”) between Big Cypress Acquisit Corp. ("Big Cypress") and SAB
Slide 3: Forward Looking Statements
Forward Looking Statements The material in this presentation has been prepared by SAB Biotherapeutics, Inc. (SAB) and is general background information about SAB’s activities current as of the date of this presentation. This information is given in summary form and is not intended to be complete. In
Slide 4: Transaction Summary
Transaction Summary Transaction Highlights + Big Cypress Acquisition Corp. (Nasdaq: BCYP) is a Life Sciences focused publicly traded Special Purpose Acquisition Company (SPAC) with ~$116 million in cash to be deployed Transaction * BCYP has entered into an agreement to combine with SAB Biotherapeuti
Slide 5: SAB Biotherapeutics Investment Overview
SAB Biotherapeutics Investment Overview * Clinical-stage, de-risked human polyclonal antibody platform applicable to broad range of indications * Significant potential clinical advantages over monoclonal antibodies and animal-derived polyclonal antibodies + Applicable to diverse therapeutic areas (T
Slide 6: Highly-Experienced Management Team
Eddie J. Sullivan, PhD PRESIDENT & CEO / CO-FOUNDER + 20years new technology development + 25+ years biotech + Former Japanese pharma + BIO Executive Committee Reproductive physiologist Charles Randall, Jr., MBA CHIEF STRATEGY OFFICER + Organizational structuring + Corporate development + Business s
Slide 7: Novel DiversitAb Platform for Developing Highly-Differentiated Immunotherapies
Novel DiversitAb”™ Platform for Developing Highly-Differentiated Immunotherapies cc) a Y Robust, growing Vertical integration Leveraged advanced clinical-stage enables rapid, genetic engineering pipeline spanning scalable & antibody science multiple development to develop therapeutic areas of multi-
Slide 8: Polyclonals: Broader Spectrum Efficacy Valuable in Range of Indications
Polyclonals: Broader Spectrum Efficacy Valuable in Range of Indications FDA: CENTER FOR DRUG EVALUATION & RESEARCH (CDER) ( Characterized = Monoclonal Antibody \s yl mAb Clones of a single antibody bind to a specific epitope Monoclonal Approach e Highly-targeted with specific activity Iterative Ab i
Slide 9: Robust Pipeline with Broad Therapeutic Reach
Robust Pipeline with Broad Therapeutic Reach Wns BIOTHERAPEUTICS Candidate Indication Preclinical Phasel Phase 2 Phase 3 SAB. SEASONAL INFLUENZA Phase |] Bebeta tient alpen steele Infectious Disease SAB-185 COVID-19 (USG FUNDED) Phase 2/3 Adpative (ACTIV-2) eee eal SAB-142 TYPE 1 DIABETES IND-Enabli
Slide 10: DiversitAb: Multi-Dimensional Immunotherapies
DiversitAb”: Multi-Dimensional Immunotherapies from Tc Bovine-Derived Human Antibody Platform Wns BIOTHERAPEUTICS Combinatorial mechanisms target diverse causes common to many human diseases Polyclonal Activates full cell effector function and complement Multi-valent Designed to bind to multiple tar
Slide 11: Multi-Pronged Business Strategy Powered by Novel Proprietary Platform
1 Multi-Pronged Business Strategy Powered by Novel Proprietary Platform Opportunity to Create New Class of Immunotherapies product Development + Demonstrated clinical safety and efficacy of Pipeline Assets: + Proof-of-platform with highly-mutating infectious disease Bee i Giaee Fist Cees @UnmeENeeds
Slide 12: Versatile Antibody Platform with Ability to Capture Multiple Markets
12 Versatile Antibody Platform with Ability to Capture Multiple Markets Human Antibody Discovery & Development Engine, New Source for IgG, Therapeutic Production Represents Multi Billion Dollar Market Opportunity + Robust pipeline across multiple therapeutic areas + Potential to capture mAb, hIVIG,
Slide 13: DiversitAb Platform
Men BIOTHERAPEUTICS DIVERSITAB™ PLATFORM
Slide 14: DiversitAb Platform
14 4 DiversitAb™ Platform PRSAb BIOTHERAPEUTICS Advancing a new class of fully-human polyclonal Tc bovine-derived antibodies without the need for human serum — Reliable, controlled, consistent production of diverse, Bi } 2 high-titer, high-avidity, fully-human polyclonal antibodies Benn ” " — . TARG
Slide 15: Genetically-Engineered Therapeutic Engine Leveraging Natural Human Immune Response
Genetically-Engineered Therapeutic Engine Leveraging 4S. Natural Human Immune Response BIOTHERAPEUTICS Mimics way that nature synergistically targets human disease complexity ~ Antigen(s) Tc Bovine™ Hyperimmunization Plasmapheresis Purified Human Human Bacteria (whole killed), Transchromosomic bovin
Slide 16: Clinically-Demonstrated Proof-of-Platform
Clinically-Demonstrated Proof-of-Platform Wns BIOTHERAPEUTICS Completed Government-Funded Phase 1 Clinical Trial MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS (MERS-COV) Confirmation of human antibody attributes & behavior * Baseline pharmacokinetics (PK) analysis completed with half-life of 28.5 day
Slide 17: Demonstrated Human Safety and Efficacy
if Demonstrated Human Safety and Efficacy 4S. Confirms Feasibility of Multi-dosing BIOTHERAPEUTICS High-dose therapy resulted in improved clinical parameters associated with reduced M. hominis burden following two subsequent infections Stopped Surgery Surgery SCig 1 2 M.hominisiH.sapion + 7 (olatve
Slide 18: Efficacy Against Mutational Drift
Efficacy Against Mutational Drift Adaptive & Cross Reactive to Mutating Strains Highly-Mutational Influenza Virus BYAM PHYLOGENIC TREE Wns BIOTHERAPEUTICS 100% Protection at All Dose Levels in Influenza Mouse Challenge B/Phuket/3073/2013 Vaccination strain Challenge strain 2008 2017 Survival op 2.8.
Slide 19: Neutralization of Monoclonal Cocktail Escape Mutations
es Neutralization of Monoclonal Cocktail 4S. Escape Mutations BIOTHERAPEUTICS Polyclonal SAB-159 Neutralizes mAb Escape Mutants PURIFIED ANTIBODY 1,000,000 ® @ esee 100,000 = * Escape 2 (>10-fold relative £10,000 to control virus) ZB 1,000 * a / * = e e® 10 J@ @ e@ Lower number e | @ 2 | . Oe@® mior
Slide 20: Pipeline Programs
Men BIOTHERAPEUTICS PIPELINE PROGRAMS
Slide 21: Highly-Potent: SAB-185 Exceeds Titers of Human Convalescent Plasma by 40X
Highly-Potent: SAB-185 Exceeds Titers of Human au PNSAb Convalescent Plasma by 40X BIOTHERAPEUTICS SARS-CoV-2 Live Virus (Munich Strain) Neutralization Evaluation (PRNT100) 7000 6400 6000 | = 5000 3 @ 4000 40X HYPERIMMUNIZATION 2 HIGHER WITH WUHAN = 3000 NEUTRALIZING SPIKE PROTEIN TITERS 2000 1000 <
Slide 22: SAB-185 Demonstrated High Neutralization Potency Against Mutants in Circulating Strains
SAB-185 Demonstrated High Neutralization Potency Against Mutants in Circulating Strains 22 /n vitro Neutralization Potency Against VSV-SARS-CoV-2 Mutants § 2] » * ' * Logg BAB (ogi) SABES Lott SAB-185 Lot 4 © SAB-185Lot6 © Negative contol higG © 204 sory E484K <2 a Ses fot ¢ § § ea ae Se WASHINGTON
Slide 23: Addresses Escape Mutants: SAB-185 Superior to Monoclonal Antibody
23 Addresses Escape Mutants: SAB-185 Superior to Monoclonal Antibody Selection for VSV-SARS-CoV-2 Wild Type Escape Mutation No Antibody SAB-185 Targeted High-Potency Polyclonal Mixture Monoclonal Ab LOT1 E484K E484A F486S No Escape Mutants Escape Mutants WASHINGTON UNIVERSITY SCHOOL OF MEDICINE-ST.
Slide 24: Overcomes Resistance: SAB-176 Demonstrated In Vivo Efficacy
Overcomes Resistance: SAB-176 Demonstrated au In Vivo Efficacy Against Oseltamivir-Resistant Viruses qe" Single dose of SAB-176 at 5mg/kg provided 100% protection from mortality Mice treated with anti-Flu hIVIG at 20mg/kg had 0% survival In-vivo Oseltamivir Resistant pH1N1 Mouse Challenge Study Intr
Slide 25: SAB-142: Potential Breakthrough Applicable to Many Autoimmune Diseases
SAB-142: Potential Breakthrough Applicable 4S. to Many Autoimmune Diseases BIOTHERAPEUTICS Superior to Widely-Used Animal Serum-Derived Immune Globulins ATGAM & Thymoglobulin Limitations of approved animal 5 H Iternati ld have significant serum-derived ATG products: pt eacoNee Ae reheat efficacy, sa
Slide 26: SAB-142: Comparable Mode of Action to Approved Products
SAB-142: Comparable Mode of Action to Approved Products SAB-142 ee 091 Tc Bovine Human-PB, Rabbit THYMO-AF488, Equine ATGAM-AF488 and Anti-CD3-APC 2 foe ono e fo 9a7 od i] aH ny mo 4 < a aie ° doz an 0083 026 RABBIT THYMO-AF488 Pes se) © 2021 SAB BIOTHERAPEUTICS, INC. - CONFIDENTIAL Wen, BIOTHERAPEU
Slide 27: Single-dose rATG Shows Sustained Benefit in Type 1 Diabetes Over Two Years
Single-dose rATG Shows Sustained Benefit in Type 1 Diabetes Over Two Years A CPeplde AUC Moan Over Time By Treaiment Group — predicted Linear Popustion Mean of -Peptise AUC Maan by Treabrent (based on Mined Mode!) a Macnee nen a SS Reow-tem seen Feel PA SS Rotecrwncwna : :-s wt. [oS + Note jo fave a
Slide 28: Unlocking Full Potential of Antibodies for Treatment of Cancers
28 Unlocking Full Potential of Antibodies for Treatment of Cancers SAB’s Human Polyclonal Antibodies Offer Many Potential Advantages as Cancer Therapies Unique ability to simultaneously target multiple modalities Multi-targeting of cancer in a single product Leverages native immune response-polyclon
Slide 29: SAB pAbs Show Increased Binding Compared to mAb at Same Target Concentrations
29 SAB pAbs Show Increased Binding Compared to mAb at Same Target Concentrations Comparative PD-L1 Cell Binding Analysis Atezolizumab SAB pAbs (Commercial mAb) (PD-L1 targeted) 600 + }' covoz0s Atezo anti-PD-L1 | Mc3B | i 1} humanized IgG1 soo | \ \ coLo205 wat a Fe-deficient | at o | } \ wot | \ f
Slide 30: Scaled Infrastructure & Capacity
30 Scaled Infrastructure & Capacity Wenn BIOTHERAPEUTICS ™ Tc Bovine & Plasma Production Facility Plasma Purification Suite (50L) | : . Manufacturing Facility (200L) 0 aaa E : 7 ys —— © 2021 SAB BIOTHERAPEUTICS, INC. - CONFIDENTIAL
Slide 31: Multiple Upcoming Catalysts through YE2022
Multiple Upcoming Catalysts through YE2022 Yen BIOTHERAPEUTICS YW O O 0 CO CO O Proof-of- concept established for DiversitAb™ Platform SAB-176 for seasonal influenza Phase 2a Challenge study initiation expected 202021 SAB-185 for COVID-19 Phase 1/1b readout expected in 402021 SAB-176 for seasonal in
Slide 32: Transaction Overview
Transaction Overview Pe sources | mount 32 Pro Forma Valuation Cash Held in SPAC Trust * $16,150,000 uum ibe $1010 : Pro Forma Shares Outstanding 43,896,590 SAB Shareholder Equity Rollover $300,000,000 Pro Forma Equity Value $443,355,562 Big Cypress Sponsor Shares $27,205,562 (-) PF Cash +34 $117,97